GUILLAIN-BARRE SYNDROME DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-134634 |   Health Care

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Guillain-Barre Syndrome Drugs Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET

7.1 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Akari Therapeutics Plc (United States)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Annexon Inc (United States)

16.3 CuraVac Inc (United States)

16.4 Hansa Medical AB (Sweden)

16.5 Vitality Biopharma Inc (United States)

16.6 Grifols, S.A. (Spain)

16.7 CSL Behring (United States)

16.8 Shire Plc (United States)

16.9 Octapharma AG (Switzerland)

16.10 Takeda Pharmaceuticals (Japan)

16.11 China Biologic Products Holdings (China)

16.12 Biotest (Germany)

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
Coversin
Immune Globulin
Others
By Application
Clinic
Hospital
Others
By Forms
Tablets
Injection

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online
Others

Companies

Akari Therapeutics Plc (United States)
Annexon Inc (United States)
CuraVac Inc (United States)
Hansa Medical AB (Sweden)
Vitality Biopharma Inc (United States)
Grifols, S.A. (Spain)
CSL Behring (United States)
Shire Plc (United States)
Octapharma AG (Switzerland)
Takeda Pharmaceuticals (Japan)
China Biologic Products Holdings (China)
Biotest (Germany)

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.